AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31383609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosilver foam (SF)
Number of subjects: 20
Study 31383609 — intervention group
Group type: COMPARATOR
Intervention: Collagen (C)
Number of subjects: 20
Study 31383609 — intervention group
Group type: COMPARATOR
Intervention: Silver nanoparticle gel (SG)
Number of subjects: 20
Study 28515079 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) 1,000 mg/6 h for 24 h before and immediately following RE
Number of subjects: 8
Study 28515079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 26262642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMN)
Number of subjects: 184
Study 26262642 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation (Fe)
Number of subjects: 184
Study 23046177 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-oriented reality program with healthy food ads
Number of subjects: 253
Study 23046177 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-oriented reality program with unhealthy food ads
Number of subjects: 253
Study 23046177 — intervention group
Group type: COMPARATOR
Intervention: Non-health-oriented reality program
Number of subjects: 253
Study 23046177 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-themed sitcom with healthy food ads
Number of subjects: 253
Study 23046177 — intervention group
Group type: COMPARATOR
Intervention: Health-themed sitcom with unhealthy food ads
Number of subjects: 253
Study 21624416 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX102 (STF2.4xM2e) at doses of 0.03 μg, 0.1 μg, 0.3 μg, and 1.0 μg
Number of subjects: 60
Study 21624416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19149344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered oxymetazoline
Number of subjects: 8
Study 19149344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered surfactant
Number of subjects: 8
Study 19149344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered acetylcysteine
Number of subjects: 8
Study 19149344 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered pseudoephedrine
Number of subjects: 8
Study 19149344 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 8
Study 16864822 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic response to transcranial magnetic stimulation (TMS)
Number of subjects: 27
Study 12618330 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation
Number of subjects: 0
Study 12618330 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1 codon 399 genotype
Number of subjects: 0
Study 12618330 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 10828770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepayment systems
Number of subjects: 860
Study 10828770 — intervention group
Group type: COMPARATOR
Intervention: No prepayment system
Number of subjects: 860
Study 9596418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous boluses of isosorbide dinitrate
Number of subjects: 72
Study 9596418 — intervention group
Group type: COMPARATOR
Intervention: Sublingual sprays of isosorbide dinitrate
Number of subjects: 72
Study 8172092 — intervention group
Group type: EXPERIMENTAL
Intervention: 40%‐fat diet with fish or fish oil
Number of subjects: 7
Study 8172092 — intervention group
Group type: EXPERIMENTAL
Intervention: 30%‐fat diet
Number of subjects: 7
Study 8172092 — intervention group
Group type: EXPERIMENTAL
Intervention: 30%‐fat diet with fish
Number of subjects: 7
Study 8172092 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily fish meal
Number of subjects: 7
Study 3151984 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (Group I: 0.08-0.33 mmol/l, mean: 0.23 mmol/l; Group II: 0.40-0.84 mmol/l, mean: 0.555 mmol/l)
Number of subjects: 44
Study 3151984 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (Group II)
Number of subjects: 44
Study 28714738 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM) intervention 'Partner in Sight'
Number of subjects: 90
Study 27121123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics training only
Number of subjects: 96
Study 27121123 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety voice training only
Number of subjects: 96
Study 27121123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ergonomics and safety voice training
Number of subjects: 96
Study 27121123 — intervention group
Group type: COMPARATOR
Intervention: Control group with no additional training intervention
Number of subjects: 96
Study 25767805 — intervention group
Group type: EXPERIMENTAL
Intervention: P. lanceolata mouth rinse
Number of subjects: 0
Study 23933905 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadoxine extended release (ER) 1400 mg/day for 6 weeks
Number of subjects: 120
Study 23933905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20642206 — intervention group
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray (200 microg)
Number of subjects: 30
Study 18560141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (eye open)
Number of subjects: 8
Study 18560141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (eye closed)
Number of subjects: 8
Study 18560141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (right hand clenching with eye open)
Number of subjects: 8
Study 18560141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (patient 2)
Number of subjects: 8
Study 16369892 — intervention group
Group type: COMPARATOR
Intervention: HRT (conjugated estrogen at a dose of 0.31 mg/day + medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 76
Study 16369892 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + alfacalcidol (1.0 microg/day)
Number of subjects: 76
Study 16369892 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HRT and HRT + alfacalcidol
Number of subjects: 76
Study 12466161 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC)
Number of subjects: 0
Study 12466161 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-site surgery
Number of subjects: 0
Study 12466161 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 0
Study 12466161 — intervention group
Group type: COMPARATOR
Intervention: Staged procedures
Number of subjects: 0
Study 12466161 — intervention group
Group type: COMPARATOR
Intervention: Alternative glaucoma procedures
Number of subjects: 0
Study 15605452 — intervention group
Group type: EXPERIMENTAL
Intervention: Avorax
Number of subjects: 12
Study 15605452 — intervention group
Group type: COMPARATOR
Intervention: Zovirax
Number of subjects: 12
Study 7882787 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure, closed suction pelvic drain for seven days
Number of subjects: 100
Study 7882787 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 100
Study 2179362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose quinidine-mexiletine combination therapy
Number of subjects: 15
Study 2179362 — intervention group
Group type: COMPARATOR
Intervention: Quinidine monotherapy
Number of subjects: 15
Study 366538 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) given by nose drops
Number of subjects: 22
Study 366538 — intervention group
Group type: COMPARATOR
Intervention: Saline alone as placebo
Number of subjects: 22
Study 6805621 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hydralazine 100 mg twice daily
Number of subjects: 20
Study 6805621 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hydralazine 200 mg once daily
Number of subjects: 20
Study 6805621 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release hydralazine 200 mg once daily
Number of subjects: 20
Study 6805621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30589722 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST verbal encouragement
Number of subjects: 23
Study 30589722 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTH verbal encouragement
Number of subjects: 23
Study 30589722 — intervention group
Group type: COMPARATOR
Intervention: HARD verbal encouragement
Number of subjects: 23
Study 30589722 — intervention group
Group type: COMPARATOR
Intervention: NO CUE verbal encouragement
Number of subjects: 23
Study 29379943 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of mixed tocotrienols twice daily for 12 months
Number of subjects: 300
Study 29379943 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 300
Study 26839066 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 26839066 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 26839066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6
Number of subjects: 18201
Study 26839066 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 18201
Study 26839066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6 and CRP
Number of subjects: 18201
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with at least 2 arterial grafts
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel at discharge
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins at discharge
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction <30%
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <40 years
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate <60 ml/min/1.73 m(2)
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐ST‐elevation myocardial infarction/ST‐elevation myocardial infarction
Number of subjects: 592
Study 24161142 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency procedure
Number of subjects: 592
Study 21779817 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized coordinator intervention
Number of subjects: 267
Study 21779817 — intervention group
Group type: COMPARATOR
Intervention: Simple fall prevention advice (control)
Number of subjects: 267
Study 19167122 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term chemotherapy (cisplatin 70 mg/m² for 1 day and 5FU 700 mg/m² for 5 days) with radiotherapy (RT) of 60Gy/30 fractions/7 weeks.
Number of subjects: 91
Study 19167122 — intervention group
Group type: COMPARATOR
Intervention: Protracted chemotherapy (cisplatin 7 mg/m² for 10 days and 5FU 250 mg/m² for 14 days) with radiotherapy (RT) of 60Gy/30 fractions/7 weeks.
Number of subjects: 91
Study 17496643 — intervention group
Group type: EXPERIMENTAL
Intervention: Current steering applied to electrode pairs (2 and 3, 8 and 9, 13 and 14)
Number of subjects: 57
Study 17496643 — intervention group
Group type: EXPERIMENTAL
Intervention: Current steering
Number of subjects: 57
Study 15688191 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 50
Study 15688191 — intervention group
Group type: COMPARATOR
Intervention: Intranasal salmon calcitonin (sCT) 200 IU/day
Number of subjects: 50
Study 11888741 — intervention group
Group type: EXPERIMENTAL
Intervention: eloHAES
Number of subjects: 22
Study 11888741 — intervention group
Group type: COMPARATOR
Intervention: gelofusine
Number of subjects: 22
Study 10213112 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy with ligation (EISL)
Number of subjects: 28
Study 10213112 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 28
Study 8869024 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3
Number of subjects: 0
Study 2120987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (0.2 ml/kg)
Number of subjects: 12
Study 2120987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, 0.2 ml/kg)
Number of subjects: 12
Study 917259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin administration
Number of subjects: 2
Study 917259 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo administration
Number of subjects: 2
Study 31122088 — intervention group
Group type: EXPERIMENTAL
Intervention: DSSFTN (Decision Support System for Total Nutrients)
Number of subjects: 38
Study 31122088 — intervention group
Group type: COMPARATOR
Intervention: Standard PN calculated by doctors
Number of subjects: 38
Study 31386463 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Randomized Benchmarking (RB) protocol using random circuits over native gates seeded by an initial layer of Clifford-like randomization.
Number of subjects: 5
Study 31386463 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Randomized Benchmarking (RB) protocol
Number of subjects: 5
Study 31386463 — intervention group
Group type: COMPARATOR
Intervention: Clifford Randomized Benchmarking (RB)
Number of subjects: 5
Study 27722908 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cancer Recovery (MBCR)
Number of subjects: 139
Study 27722908 — intervention group
Group type: COMPARATOR
Intervention: Supportive Expressive Group Therapy (SET)
Number of subjects: 139
Study 27406988 — intervention group
Group type: EXPERIMENTAL
Intervention: Y grafting configuration
Number of subjects: 304
Study 27406988 — intervention group
Group type: COMPARATOR
Intervention: in situ configuration
Number of subjects: 304
Study 27406988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both configurations
Number of subjects: 304
Study 25335963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus treatment as usual
Number of subjects: 0
Study 25335963 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 0
Study 22075018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.3%
Number of subjects: 76
Study 22075018 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (Placebo)
Number of subjects: 76
Study 19356306 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of docosahexaenoic acid (DHA)
Number of subjects: 90
Study 19356306 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of docosahexaenoic acid (DHA)
Number of subjects: 90
Study 19356306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18693828 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information technology intervention 1
Number of subjects: 17000
Study 18693828 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information technology intervention 2
Number of subjects: 17000
Study 18693828 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information technology intervention 3
Number of subjects: 17000
Study 14691117 — intervention group
Group type: EXPERIMENTAL
Intervention: APF+FD
Number of subjects: 16
Study 14691117 — intervention group
Group type: EXPERIMENTAL
Intervention: APF+PD
Number of subjects: 16
Study 14691117 — intervention group
Group type: COMPARATOR
Intervention: FD
Number of subjects: 16
Study 14691117 — intervention group
Group type: COMPARATOR
Intervention: PD
Number of subjects: 16
Study 12486792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole at 100-400 mg daily for the first 1-3 months post-liver transplantation
Number of subjects: 0
Study 12486792 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled liposomal preparations post-organ transplantation or preemptive use of itraconazole
Number of subjects: 0
Study 12486792 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic techniques for identification and preemptive therapy
Number of subjects: 0
Study 10340968 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (attended for follow up)
Number of subjects: 558
Study 10340968 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (difficult to trace)
Number of subjects: 558
Study 10340968 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (very reluctant for assessment)
Number of subjects: 558
Study 10340968 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cohort
Number of subjects: 558
Study 8846750 — intervention group
Group type: EXPERIMENTAL
Intervention: Contractubex gel (10% onion extract, 50 U sodium heparin per g of gel, 1% allantoin)
Number of subjects: 65
Study 8846750 — intervention group
Group type: EXPERIMENTAL
Intervention: Contractubex gel
Number of subjects: 65
Study 8846750 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 65
Study 2193980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g per day)
Number of subjects: 4524
Study 2193980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4524
Study 507117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral group (medroxyprogesterone 50 mg three times a day)
Number of subjects: 22
Study 507117 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular group (medroxyprogesterone 300 mg weekly)
Number of subjects: 22
Study 507117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral group
Number of subjects: 22
Study 507117 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular group
Number of subjects: 22
Study 31361767 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 male condoms
Number of subjects: 10245
Study 31361767 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Counseling and Testing (VCT) only
Number of subjects: 10245
Study 31361767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VCT and condoms
Number of subjects: 10245
Study 31361767 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither program)
Number of subjects: 10245
Study 28644244 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic training with controlled force applied to pelvis and legs
Number of subjects: 23
Study 28644244 — intervention group
Group type: COMPARATOR
Intervention: Treadmill only training with manual assistance as needed
Number of subjects: 23
Study 26631327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated diet with glucose restriction (DG)
Number of subjects: 51
Study 26631327 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study 24668638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mg)
Number of subjects: 70
Study 24668638 — intervention group
Group type: COMPARATOR
Intervention: Dicaine (20 mg)
Number of subjects: 70
Study 21963266 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5%
Number of subjects: 400
Study 21963266 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.1%
Number of subjects: 400
Study 21963266 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 400
Study 21963266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from ATOM1)
Number of subjects: 400
Study 21963266 — intervention group
Group type: COMPARATOR
Intervention: Atropine 1% (from ATOM1)
Number of subjects: 400
Study 21963266 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.1% and 0.5%
Number of subjects: 400
Study 19436994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (n=15)
Number of subjects: 90
Study 19436994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ketamine (n=16)
Number of subjects: 90
Study 19436994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine users (n=18)
Number of subjects: 90
Study 19436994 — intervention group
Group type: COMPARATOR
Intervention: Polydrug controls (n=19)
Number of subjects: 90
Study 19436994 — intervention group
Group type: COMPARATOR
Intervention: Nondrug-using controls (n=17)
Number of subjects: 90
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glibenclamide
Number of subjects: 30
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg glibenclamide
Number of subjects: 30
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg glibenclamide
Number of subjects: 30
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine requirements
Number of subjects: 30
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary hemodynamics
Number of subjects: 30
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Global oxygen transport
Number of subjects: 30
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas exchange
Number of subjects: 30
Study 17589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytes
Number of subjects: 30
Study 14693962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise (75% HRR)
Number of subjects: 18
Study 14693962 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (50% HRR)
Number of subjects: 18
Study 14693962 — intervention group
Group type: COMPARATOR
Intervention: Moderate and intense exercise
Number of subjects: 18
Study 11476835 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental manipulation (active HRA)
Number of subjects: 291
Study 11476835 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control HRC)
Number of subjects: 291
Study 11476835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk infants (LR)
Number of subjects: 291
Study 9683310 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; beta-carotene, 6 mg) and minerals (selenium, 100 microg; zinc, 20 mg)
Number of subjects: 12735
Study 9683310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12735
Study 7941961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral SAMe
Number of subjects: 26
Study 7941961 — intervention group
Group type: COMPARATOR
Intervention: Oral desipramine
Number of subjects: 26
Study 7941961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 3068098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g as a single dose
Number of subjects: 247
Study 3068098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g on 2 consecutive days
Number of subjects: 247
Study 3068098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247